

University of Groningen

## Erythropoietin in cardiac ischemia

Lipsic, Erik

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2006

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Lipsic, E. (2006). *Erythropoietin in cardiac ischemia*. [Thesis fully internal (DIV), University of Groningen]. [s.n.].

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## Erythropoietin in cardiac ischemia

The cover illustration depicts the face of Janus, Roman god of gates and beginnings. Janus was frequently used to symbolize change and transition, one face reflecting on the past while the other face looks forward into the future. In cells, erythropoietin activates JAK (Janus kinase), which contains two domains critical for signal transduction. The two faces of Janus may also symbolize the “old” hematopoietic and “new” non-hematopoietic functions of erythropoietin, as well as the two effects of erythropoietin in the heart: inhibition of apoptosis and stimulation of neovascularization.

Financial support by the Groningen University Institute of Drug Exploration (GUIDE) and Van Buchem Stichting for the publication of this thesis is gratefully acknowledged.

ISBN 90-367-2567-4

© Copyright Erik Lipšic, 2006

All rights reserved. No part of this publication may be reproduced, or transmitted in any form or by any means, without permission of the author.

Layout: Helga de Graaf, Studio Eye Candy te Groningen. ([www.proefschrift.info](http://www.proefschrift.info))

Printed by: Ipskamp PrintPartners Enschede, The Netherlands.

RIJKSUNIVERSITEIT GRONINGEN

# Erythropoietin in cardiac ischemia

Proefschrift

ter verkrijging van het doctoraat in de  
Medische Wetenschappen  
aan de Rijksuniversiteit Groningen  
op gezag van de  
Rector Magnificus, dr. F. Zwarts,  
in het openbaar te verdedigen op  
maandag 8 mei 2006  
om 14.45 uur

door

Erik Lipšic  
geboren op 8 juli 1973  
te Bratislava (Slowakije)

Promotores:

Prof. Dr. W.H. van Gilst  
Prof. Dr. D.J. van Veldhuisen

Copromotores:

Dr. R.G. Schoemaker  
Dr. A.A. Voors

Beoordelingscommissie:

Prof. Dr. P. Ponikowski  
Prof. Dr. F. Zijlstra  
Prof. Dr. A.J. van Zonneveld

Paranimfen:

Peter van der Meer  
Peter Ochodnický

Publication of this thesis was financially supported by: Amgen BV, Astellas Pharma BV, Bayer BV, Boehringer Ingelheim BV, Merck Sharp & Dohme BV, Pfizer BV, Roche Nederland BV, Sanofi-Aventis, Servier Nederland Farma BV, AstraZeneca BV, Janssen-Cilag BV, St. Jude Medical Nederland BV.



Per vivere tranquilli occorrono cinque cose:

1. un bicchiere di scienza
2. una bottiglia di sapienza
3. un barile di prudenza
4. una botte di coscienza
5. un mare di pazienza

S.Alfonso

To the memory of Peter Kubica,  
exceptional person,  
best friend,  
.....we shall overcome.





## Contents

Chapter 1	General introduction and aims of the thesis	11
Chapter 2	Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury <i>Eur J Heart Fail 2004;6(7):853-9</i>	21
Chapter 3	Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion <i>J Cardiovasc Pharmacol 2004;44(4):473-9</i>	35
Chapter 4	Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction <i>J Am Coll Card 2005;46(1):125-33</i>	51
Chapter 5	Erythropoietin attenuates heart failure in a hematocrit independent manner <i>Submitted</i>	69
Chapter 6	A single bolus of a long-acting erythropoietin analogue darbepoetin in patients with an acute myocardial infarction: a randomized feasibility and safety study. <i>Cardiovasc Drugs Ther 2006; in press</i>	85
Chapter 7	Hemoglobin levels and 30-day mortality in patients after myocardial infarction <i>Int J Cardiol 2005;100(2):289-92</i>	99
Chapter 8	Protective effects of erythropoietin in cardiac ischemia: from bench to bedside (review article) <i>Submitted</i>	109
Chapter 9	Summary and conclusions	127
	Samenvatting en conclusies	135
	Zhrnutie a záver	141
	Dankwoord	147
	Bibliography	153

